ClinicalTrials.gg
Active, not recruitingNCT05326243Updated Oct 9, 2026

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

A Phase 1/2 interventional study of CD19-targeted chimeric antigen receptor T-cell in Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma and Large B-cell Lymphoma, sponsored by Pell Bio-Med Technology Co., Ltd.. Active, not recruiting at 5 sites in Taiwan. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Pell Bio-Med Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan — 5 open to participants now, 19 under way, 10 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Taiwan.

Planned enrollment
29th of 34
49 · median 359
Started
2022
with 2 others
Phase 1/2
4 of 37
1 open now
Primary completion
2026-12
later than 4 of 18 live
Registered
28th of 37
by date
Lead sponsor
2 of 37
Pell Bio-Med Technology Co., Ltd.

Among the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, this one is the 29th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 18 other live ones, and was the 28th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

5 of the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, or all of them as a file.
02

Study summary

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

Read the detailed description

Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) were licensed by the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) in 2017 to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and High-grade B-cell lymphoma (HGBCL). A third anti-CD19 CAR-T product, Tecartus (brexucabtagene autoleucel, Gilead) was approved by the US FDA for relapsed and refractory mantle cell lymphoma (MCL) in July 2020. In February 2021, another product, Breyanzi® (lisocabtagene maraleucel, Juno Therapeutics, Inc.), was approved by the US FDA for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, Primary mediastinal large B cell lymphoma (PMLBCL), and Gr. 3b FL.

Currently, in Taiwan, no CD19 CAR-T therapies are available commercially.This Phase 1/Phase 2 study will test PL001, a CD19 CAR-T therapy manufactured by Pell Bio-Med Technology Co., Ltd., as a monotherapy for relapsed or refractory B-cell lymphoma. The Phase 1 of the study will be conducted to establish a dose range that is well tolerated by the majority of patients and to provide a safety profile of PL001 in the target patient population. The results of the Phase 1 of the study will recommend the dose selection for the Phase 2 of the study. Phase 2 of the study will assess the efficacy and safety of PL001 in patients with relapsed or refractory B cell lymphoma.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Follicular Lymphoma Grade 3A
  • Follicular Lymphoma Grade 3B

Keywords

  • DLBCL
  • PMLBCL
  • FL
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening 1:

  1. Patient is ≥14 years of age, inclusive, at the time of signing the .
  2. confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL), large B-cell lymphoma transformed from follicular lymphoma (FL), or grade 3a or 3b FL.
  3. On-site documentation of CD19 on the dominant population of cancer cells.
  4. Disease status should meet any one of the below:

    1. Patients with previous -hematopoietic stem cell transplantation (auto HSCT) have , progressive, or refractory disease (defined as having not achieved a CR) after transplantation regardless of .
    2. Patients without previous HSCT have relapsed, progressive, or refractory disease (defined as having not achieved a CR) after at least 2 lines of systemic therapy, including anti-CD20 antibody and anthracycline.
  5. Have no available effective systemic therapy as judged by the Investigator.
  6. At least one measurable non-CNS (central nervous system) lesion based on Lugano classification for lymphoma.
  7. (ECOG) performance status of 0 to 2.
  8. of at least 3 months.
  9. Patient is male or female.
  10. A male patient must agree to use a highly effective as detailed in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating sperm during this period.

    Female Patients:

  11. A female patient is eligible to participate if she is not pregnant (Section 10.4; Appendix 4), not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of (WOCBP) as defined in Section 10.4 (Appendix 4).

    OR

    • A WOCBP who agrees to follow the contraceptive guidance in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating ova during this period.
  12. Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Screening 2:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  2. CAR-T is successfully manufactured and ready for use, from cells harvested by non mobilized leukapheresis.
  3. WOCBP who have a negative serum pregnancy test at Screening 2.

Exclusion criteria

Exclusion Criteria:

Screening 1:

  1. Chronic lymphocytic leukemia with Richter's transformation.
  2. Primary CNS lymphoma. (Non-primary CNS lymphoma with CNS involvement is eligible).
  3. Primary intra-ocular lymphoma.
  4. Prior CD19 targeted therapy, such as CAR-T, Bi-specific T-cell engagers (BiTE), or monoclonal antibody.
  5. History of cancers (includes myelodysplastic syndrome) other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free without active treatment for at least 3 years.
  6. History of HSCT.
  7. History of autologous HSCT within 3 months prior to consent.
  8. Received any product within 4 weeks prior to consent.
  9. Systemic anticancer therapy within 3 weeks prior to apheresis.
  10. Long-term use of systemic , defined as daily use >10 mg of prednisolone or equivalent, within 2 weeks prior to leukapheresis.

    Exception examples:

    • Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
    • Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
    • Low dose maintenance steroid therapy for other conditions (e.g., asthma).
  11. Use of long-acting and short-acting myeloid growth factor within 2 weeks, 5 days prior to leukapheresis, respectively.
  12. Received anti-thymocyte globulin within 4 weeks prior to consent.
  13. Intrathecal chemotherapy within 1 week prior to leukapheresis.
  14. Inadequate major organ functions at Screening, which were defined as any of below:

    1. (ANC) \<500/µL
    2. Absolute lymphocyte count (ALC) \<300/µL, excluding leukemic cells.
    3. (Hb) \<8.0 g/dL
    4. count \<75,000/µL without transfusion support within 3 days
    5. e. Baseline O2 saturation \<92% by pulse oximetry at room air
    6. Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
    7. (AST) >5 × (ULN) and alanine aminotransferase (ALT) >5 × ULN, or total >2 × ULN (except for constitutional jaundice)
    8. Serum creatinine > 1.5 × ULN and estimated (eGFR) \< 60 mL/min/1.73 m², as calculated by the formula.
    9. Significant cardiac disease including but not limited to: (LVEF) \<50%, (the corrected QT interval) > 480 msec based on Fredericia's formula, arrhythmias, history of myocardial infarction or unstable angina within 3 months prior to consent.
  15. Active virus (HBV) infection defined as detectable HBV DNA (Patients with positive anti-hepatitis B core antibody [HBcAb] must consent to regular monitoring of HBV DNA, and anti-HBV prophylaxis with oral anti-viral agent (such as entecavir) is mandatory until End-of-Study visit [Visit 15].)
  16. Active virus (HCV) infection defined as positive anti- HCV antibody plus detectable HCV RNA.
  17. Positive for (HIV) or human T-cell lymphotropic virus (HTLV) infection.
  18. Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g., the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to apheresis).

21. Any medical conditions which might compromise the patient's safety from leukapheresis, lymphodepletion chemotherapy, or CAR-T therapy and anticipated AEs, according to the Investigator's evaluation.

22.Patients with insufficient leukapheresis cells.

Screening 2:

  1. Inadequate major organ functions at Screening which were defined as any of below:

    1. ANC \<500/µL
    2. Hb \<8.0 g/dL
    3. Platelet count \<50,000/µL, without transfusion support within 3 days
    4. Baseline O2 saturation \<92% by pulse oximetry on room air
    5. AST >5 × ULN and ALT>5 × ULN, or total bilirubin >2 × ULN (except for constitutional jaundice)
    6. Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
    7. Serum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula.
  2. Long-term use of systemic corticosteroids, defined as daily use >10 mg of prednisolone or equivalent.

    Exception examples:

    • Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
    • Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
    • Low dose maintenance steroid therapy for other conditions (e.g., asthma).
  3. Use of long-acting and short-acting myeloid growth factor within 12 days, 2 days prior to lymphodepletion therapy, respectively.
  4. Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g. the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to lymphodepletion).
  5. Any medical condition which might compromise the patient's safety because of lymphodepletion chemotherapy or CAR-T therapy and anticipated AEs, according to the Investigator's opinion.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    CD19-targeted chimeric antigen receptor T-cell

    Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.

    Biological: CD19-targeted chimeric antigen receptor T-cell

Interventions

  • BiologicalCD19-targeted chimeric antigen receptor T-cell

    Drug: Fludarabine patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Drug: Cyclophosphamide patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Biological: CD19 CAR-T CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis.

    Also known as: PL001

06

What researchers measure

Primary outcomes

  1. Phase 1: Dose-limiting toxicities

    Dose-limiting toxicities through 30 days after PL001 infusion

    Time frame: 30 days

  2. Phase 2: best overall response (BOR)

    The best overall response (BOR) comprising patients with partial and complete responses according to Lugano criteria assessed based on the image review result provided by the Independent Central Review from the start of infusion of PL001 until next subsequent cancer-specific therapy, disease progression, death, or end of study, whichever comes first

    Time frame: 12 months

Secondary outcomes

  1. Phase 1 and Phase 2: Treatment-related adverse events

    Treatment-related adverse events assessed by CTCAE v 5.0. Overall grading of Cytokine Release Syndrome, immune effector cell associated neurotoxicity syndrome, based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria.

    Time frame: 12 months

  2. Phase 1 and Phase 2: Best overall response (BOR)

    The BOR of patients with partial and complete responses according to Lugano criteria assessed by the Investigator.

    Time frame: 12 months

  3. Phase 1 and Phase 2: Median duration of response (mDOR)

    Median duration of response (mDOR) measured from the time of initial documented response (complete response or partial response) until documented disease progression or death.

    Time frame: 12 months

  4. Phase 1 and Phase 2: Progression-free survival (PFS)

    Progression-free survival (PFS) defined as the time from the infusion of PL001 until objective disease progression or death, whichever occurs first.

    Time frame: 12 months

  5. Phase 1 and Phase 2: Overall survival (OS)

    Overall survival (OS) defined as the time from the infusion of PL001 until death from any cause.

    Time frame: 12 months

  6. Phase 1 and Phase 2: the health-related quality of life (HRQoL)

    Change in the health-related quality of life (HRQoL) by FACT-Lym (the Functional Assessment of Cancer Therapy-Lymphoma)® version 4

    Time frame: 12 months

Other outcomes

  1. Phase 1 and Phase 2: Pharmacokinetic (PK) profile of PL001-Persistence of PL001 by flow cytometry

    Persistence of PL001 in peripheral blood using flow cytometry

    Time frame: 12 months

  2. Phase 1 and Phase 2: Pharmacokinetic (PK) profile of PL001-Persistence of PL001 by qPCR

    PL001 transgene levels by qPCR (quantitative polymerase chain reaction) in peripheral blood

    Time frame: 12 months

  3. Phase 1 and Phase 2: Quality assurance of the product

    Rates for successful production and infused patients

    Time frame: [From start of CAR-T manufacturing to CAR-T infusion, estimated to be 45 days]

  4. Phase 1 and Phase 2: To assess the cytokine biomarkers

    Cytokine concentrations in peripheral blood

    Time frame: 12 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 55 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Dec 2026 and completion Mar 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 13, 2022
StartActual
May 31, 2022
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Mar 31, 2027was Mar 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 9, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 Taiwan)
  • National Taiwan University Hospital · Taipei, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
  • Chi Mei Medical Center · Tainan, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital · Taipei, Taiwan
Show 4 removed
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
  • Chi Mei Medical Center · Tainan City, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital · Taipei city, Taiwan
  • National Taiwan University Hospital · Taipei, Taiwan
Oct 9, 2026
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 9, 2026
Study completion
Mar 31, 2026→Mar 31, 2027
Oct 9, 2026
Eligibility
Maximum age 70 Years→none; 1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatient is ≥14 to 70 years of age, inclusive, at the time of signing the informed consent.
Exclusion criteria
  • EditedEstimatedSerum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula with overweight adjustment.
  • EditedSerum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula with overweight adjustment.
Oct 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPhase 2: best overall response (BOR): how it is measured was reworded
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Active, not recruiting
    4 sites added, 4 sites removed
    Show 4 added (4 Taiwan)
    • National Taiwan University Hospital · Taipei, Taiwan
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
    • Chi Mei Medical Center · Tainan, Taiwan
    • Taipei Medical University - Taipei Medical University Hospital · Taipei, Taiwan
    Show 4 removed
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
    • Chi Mei Medical Center · Tainan City, Taiwan
    • Taipei Medical University - Taipei Medical University Hospital · Taipei city, Taiwan
    • National Taiwan University Hospital · Taipei, Taiwan
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Mar 31, 2026→Mar 31, 2027
    Eligibility Maximum age 70 Years→none; 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatient is ≥14 to 70 years of age, inclusive, at the time of signing the informed consent.
    Exclusion criteria
    • EditedEstimatedSerum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula with overweight adjustment.
    • EditedSerum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula with overweight adjustment.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPhase 2: best overall response (BOR): how it is measured was reworded
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05326243
Lead sponsor
Pell Bio-Med Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
May 31, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Chen-Lung Lin, MD
study chair · Pell Bio-Med Technology Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion